Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Rodman & Renshaw Annual Global Investment Conference 2011
27 slides from Genetic Technologies's conference presentation, Sep 13, 2011
Slide 1: Investor presentation at Rodman & Renshaw
For personal use only ASX ANNOUNCEMENT 13 September 2011 ___________________________________________________________________________________ Investor presentation at Rodman & Renshaw Annual Global Investment Conference in New York Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that th
Slide 2: Genetic Technologies Limited – Rodman & Renshaw Healthcare Conference
For personal use only GENETIC TECHNOLOGIES LIMITED (GENE:NASDAQ, GTG:ASX) Rodman & Renshaw Healthcare Conference: September 2011
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 4: Introduction
Introduction For personal use only Currently in the 2nd year of a 5 year strategy to build a global cancer diagnostics business BREVAGen™ is the first product in this expansion Launched USA June 2011 Breast cancer risk test – buccal (cheek) swab Attractive gross margins and est. $620m pa addressable
Slide 5: Established Genetic Testing Business
Established Genetic Testing Business For personal use only Dominant market positions PacRim Globally accredited laboratory Experience producing & selling genetic tests Oncology testing Australia, Asia & EU Contracted provider to NSW Police Force for volume crime forensic testing 50+% market share Au
Slide 6: Licensing: Non-Dilutive Funding Source
Licensing: Non-Dilutive Funding Source For personal use only Non-coding DNA patent estate is one of GTG’s core assets $65m+ licensing revenue received to date 9 Licenses granted FY2011 to date for total $14.2m Contracted annuity stream of $7m in total to 2015 Foundational patent families protecting
Slide 7: Industry Scope and Available Markets
Industry Scope and Available Markets For personal use only `179 INTRON SEQUENCE ANALYSIS AGRIGENETICS TRAIT SELECTION LABS GENOMIC MAPPING IVDs EQUIPMENT NON-CODING PATENTS SEQUENCING PHARMA EQUIPMENT COMPANIES `179 Licensed AGRIGENETICS GWAS `762 Licensed `762 GENOMIC Unlicensed MAPPING 6
Slide 8: Patent Assertion Program
Patent Assertion Program For personal use only IP assertion program with off balance sheet funding Sheridan Ross in Denver driving legals 1st suit filed Feb 2010 All 9 parties settled prior to trial for total of over $5 million 2nd suit filed Jan 2011 All but one party in settlement discussions 3rd
Slide 9: Cancer Diagnostics Focus
Cancer Diagnostics Focus For personal use only New technologies driving personalized medicine & extending lives Molecular diagnosis of cancer is most attractive segment of diagnostics industry Focused market & efficient sales process Accelerating growth forecast next 4 years Global market exposure v
Slide 10: Portfolio Strategy
Portfolio Strategy For personal use only G1 in validation Colorectal / Uterine Cancer KRas Launched 2006 BRaf EGFR 2004 PacRim launch G2 in development with partner KRas June 2011 US launch BRaf EGFR Developing a portfolio of tools across cancer management spectrum, focus Developing &/or acquiring p
Slide 11: BREVAGen™
BREVAGen™ For personal use only Novel, validated test for non-familial breast cancer risk, published JNCI Oct2010 US$600m per annum US market opportunity Attractive gross margin - buccal swab Launched in 8 initial US territories June2011 High profile Key Opinion Leaders involved Experts at Stanford,
Slide 12: BREVAGen™: What does it Mean Clinically?
BREVAGen™: What does it Mean Clinically? For personal use only BREVAGen™ classifies a woman’s 5 year & lifetime risk of non-familial breast cancer, the commonest variety Test combines population risk factors with 7 genetic biomarkers (SNPs) to give an integrated, individual breast cancer risk assess
Slide 13: BREVAGen™ Performance For Risk Prediction
BREVAGen™ Performance For Risk Prediction For personal use only Mealiffe ME, et al., Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information; (2010). Journal of the National Cancer Institute 102: 1-10. 1. BREVAGen™ risk reclassification results from 3
Slide 14: BREVAGen™ – Supports Existing ASCO & ACS Guidelines
BREVAGen™ – Supports Existing ASCO & ACS Breast Cancer Management Guidelines For personal use only Positive mammogram 1.6m breast biopsy patients pa (US) 65% or 1m patients at intermediate risk due abnormal pathology Preventive therapy can prevent 50-70% cancers if targeted via BREVAGen™ Analysis re
Slide 15: Target Patient Groups
Target Patient Groups For personal use only Target market build Initial target markets 1,521 High Value MD/OBGYNs with high numbers of BRCA patient tests identified 80-90% of BRCA results are negative, plus other higher risk patients ,200-300k pa 1.6m breast biopsies in total pa Mammograms 1m atypic
Slide 16: National View of the Initial Territories
National View of the 8 Initial Territories For personal use only Selected on the basis of: CLIA status - Reimbursement ease - Patient clustering 15
Slide 17: BREVAGen™ Rest of World
BREVAGen™ Rest of World For personal use only Substantial additional opportunities exist in Europe and PacRim Some re-calibration of algorithm may be needed for some European populations Status of existing dossier would enable reasonably rapid CE marking Assessment of initial EU target markets and d
Slide 18: Established Facilities
Established Facilities For personal use only Genetic Technologies Limited Fitzroy, Vic, Australia Technical & corporate support and globally accredited sample processing. ISO, RCPA, NATA & CLIA certified. Phenogen Sciences Inc Charlotte, North Carolina, USA Sales & marketing, customer support, reimb
Slide 19: BREVAGen™ Competitors
BREVAGen™ Competitors For personal use only deCODE (Iceland) Launched in October 2008 by deCODE Genetics, no validation deCODE Breast Cancer test assesses risk based on 16 common SNPs, ordered only via MDs. Price = $1,650 Emerged from Chapter 11 in April 2010 as a private company – no US presence si
Slide 20: Execution Capability & Monitoring
Execution Capability & Monitoring For personal use only Quantitative Strategic Risk Register allows monitoring, measurement and reporting of key success factors Developed with assistance from Marsh Risk Consulting Items tracked and managed include: KOL development Medical marketing success factors L
Slide 21: Management Expertise
Management Expertise For personal use only Dr. Paul MacLeman CEO Tom Howitt, International diagnostics, Chief Finance Officer therapeutics 20 years of expertise in public Co. governance commercialization and investment banking and capital raising experience and expertise Dr. David Sparling Lewis Stu
Slide 22: Product Portfolio
Product Portfolio For personal use only Target Discovery Clinical Regulatory and Validation Review Launch and Selection Studies or CLIA Release Marker Clinical Launch Claim Validation Utility Planning Extension Studies & Studies Publication BRCA/HNPCC/SCN1A (EU/PacRim) BREVAGEN™ KRAS/BRAF/EGFR (FPFE
Slide 23: Portfolio Revenue Growth
Portfolio Revenue Growth For personal use only BREVAGen™ the first Collaboration with multi- global product in the national pharmaco cancer diagnostics strategy Followed by introduction of generic theranostic markers late Y2 Y3 introduction of blood based G2 products Companion Dx and M&A in addition
Slide 24: Growth Strategy
Growth Strategy For personal use only GTG acquired, validated and integrated BREVAGen™ as a near to market asset 2010 MDx assets are currently cheaper to buy than to develop Actively assessing new product acquisitions Seeking: On or close to market assets Similar sales channels and marketing synergi
Slide 25: Financial Snapshot June 2011
Financial Snapshot June 2011 For personal use only Financials (12 months to Jun30) Share Register (AUD millions) 2011 2010 Shares outstanding 464.6m Revenue 18.3 8.7 Top 20 shareholders 76% Operations* 4.6 4.9 Total shareholders 2,850 Licensing 13.7 3.8 Options outstanding ** 19.7m Net income / (los
Slide 26: Summary
Summary For personal use only GTG launched world’s first validated test for non- familial breast cancer risk Jun11 BREVAGen™ has attractive CoGS & rapid payback Target market is global, characterized & large US sales, marketing & reimbursement infrastructure established GTG has a sound base of relia
Slide 27: Contact Details
Contact Details For personal use only Dr Paul D R MacLeman CEO Genetic Technologies Limited Phone +61 3 8412 7000 Email info@gtglabs.com 26
Genetic Technologies — Rodman & Renshaw Annual Global Investment Conference 2011 on 6ix